Introduction {#s1}
============

Unlike normal cells, most cancer cells depend on a high rate of glycolysis for energy production during malignant progression. This is known as the Warburg effect and is considered the seventh hallmark of cancer [@pone.0080576-Hanahan1]. This effect has been exploited in 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (^18^F-FDG PET/CT) technologies, which has proved highly successful in clinical practice and is widely applied in tumor diagnosis [@pone.0080576-Carins1], [@pone.0080576-Li1].

The maximal standardized uptake value (SUV~max~) determined through PET imaging is a simple and reliable method of evaluating the glucose uptake capacity of tumors *in vivo*. It is defined as the ratio of activity in tissue per unit volume to the activity in the injected dose per patient body weight [@pone.0080576-Katsuhiko1]. Recent reports have demonstrated that the SUV~max~ of primary tumors is correlated with the stage, nodal status, histologic type, differentiation and progression of tumors [@pone.0080576-Minghuan1], [@pone.0080576-Bille1]. Furthermore, a high SUV~max~ has been linked with poor prognosis in cancer patients [@pone.0080576-Vesselle1].

Despite these observations, further investigations are required to establish the clinical value of ^18^F-FDG PET/CT imaging for tumor diagnosis, by identifying the metabolic enzymes and abnormal expressions of cancer genes that underlie SUV~max~ changes in cancer tissues. Therefore, many studies have focused on defining the relationship between FDG uptake and the expression of tumor biomarkers, including nuclear- associated antigen Ki-67, cyclooxygenase-2 (Cox-2), vascular endothelial growth factor (VEGF) and the glucose transporter 1 (GLUT1) in relation to lung cancer [@pone.0080576-Katsuhiko1], [@pone.0080576-Taylor1], [@pone.0080576-Maiko1]. To date, these have reported a correlation between SUV~max~ and tumor biomarkers and have contributed to understanding the Warburg effect and identifying tumor-related genes that are associated with the SUV, thereby providing a robust basis for staging, prognosis and personalized treatment of cancers.

Tp53-induced glycolysis and apoptosis regulator (*TIGAR*) is a novel gene related to the glucose metabolism in tumor cells [@pone.0080576-Li2]. *TIGAR* inhibits glycolysis by limiting the level of fructose-2, 6-bisphosphate (Fru-2, 6-BP) in the cell by functioning as a Fru-2, 6-bisphosphatase (Fru-2, 6-BPase). It was commonly believed that induction of *TIGAR* led to glycolysis inhibition of the cancer suppressor, *P53* [@pone.0080576-Corcoran1]. More recent studies have suggested that *TIGAR* expression increases NADPH levels through activation of the pentose phosphate pathway (PPP), thereby promoting antioxidant function which reduces reactive oxygen species (ROS)-associated apoptosis and enhances cancer cell survival [@pone.0080576-Bensaad1]. However, these studies were conducted on a limited number of cell lines through intervening transient expression experiments; therefore, it remains to be established whether *TIGAR* expression is correlated with SUV on FDG-PET and tumor prognosis in clinical practice, by acting as a suppressor gene of glucose metabolism.

The purpose of this present study was to assess the correlation between SUV~max~ and the expression of selected markers associated with tumor metabolism, namely, glucose transporter 1(*GLUT1*), hexokinase 2 (*HK2*), pyruvate kinase M2 (*PKM2*), lactate dehydrogenase A (*LDHA*), protein kinase B (*AKT*) and *TIGAR*. In addition, the relationship between the *TIGAR* expression and prognosis in non-small cell lung carcinoma (NSCLC) was investigated. We selected 79 NSCLC cases for this study, with the aim of identifying novel biological indictors for clinical diagnosis and personalized treatment options, by analyzing the relationship between SUV and key regulatory factors in glucose metabolism.

Patients and Methods {#s2}
====================

Ethics Statement {#s2a}
----------------

The Human Investigation Ethical Committee of Shanghai Jiao Tong University affiliated Renji Hospital and Shanghai Chest Hospital approved this study. All procedures involving human specimens were performed with written informed consent according to the Declaration of Helsinki.

Study Population {#s2b}
----------------

This was a retrospective study of all patients who were confirmed to have NSCLC based on histopathological finding and underwent surgery after ^18^F-FDG PET/CT between December 2006 and December 2009 at Shanghai Jiaotong University affiliated Renji Hospital and Shanghai Chest Hospital. Eligibility criteria were (1) without receiving chemotherapy/ radiotherapy before PET/CT scanning; (2) tumor pathology of NSCLC (excluded benign lung lesions and small cell lung cancers); (3) complete case records; (4) performed PET/CT scanning no more than 2 weeks prior to surgery; (5) available tissue specimen for IHC staining. Finally, 79 patients (50 male and 29 female) with a median age of 61 (range, 30--79 years) were evaluated in this study. All clinical and pathological findings were reviewed from three hospitals in Shanghai, China (Renji Hospital, Shanghai Chest Hospital, Ruijin Hospital).

PET/CT imaging {#s2c}
--------------

A dedicated whole-body PET/CT tomography (SIMENS) was used for all PET/CT imaging. Image acquisition was performed with an integrated PET/CT device. Immediately after CT scanning, PET was performed to cover the identical axial field of view. PET-image data sets were reconstructed iteratively with segmented correction for attenuation using the CT data. For semi-quantitative analysis of the ^18^F-FDG uptake, irregular regions of interest (ROIs) were placed over the most intense area of ^18^F-FDG accumulation. The maximum SUV (SUVmax) was calculated using following formula: maximum pixel value with the ROI activity (MBq/kg)/(injected dose \[MBq\]/body weight \[kg\]). Two experienced nuclear medicine physicians, blinded to the clinical history, independently evaluated the PET images and reached a consensus on all image results.

Immunohistochemical Staining {#s2d}
----------------------------

Immunohistochemical analyses were performed on paraffin-embedded lung cancer tissues. After microtome sectioning (4 µm slices), the slides were processed for staining. All primary antibodies (*TIGAR*, *GLUT-1*, *HK-2, PKM-2, LDHA, AKT*) were purchased from Abcam. Sections were assessed using a light microscope (BX51TR, Olympus, Japan) by 2 independent observers. The expression of each marker protein was examined and statistical software (DFC320 CCD system, Leica, Germany) was used for semi-quantitative analysis of IHC staining. The slides were scored for intensity of staining (0 to 3) and the percentages of cells with scores of 0 (0%), 1 (1% to 9%), 2 (10% to 49%), and 3 (50% to 100%) were determined. The immunohistochemistry (IHC) score (0 to 9) was defined as the product of the intensity and percentage of cells. Protein expression was judged as positive when the IHC score was greater than or equal to 4. All IHC results were evaluated by 2 experienced observers who were blind to the condition of the patients. Where discrepancies occurred by 2 readers, the 2 readers reached a consensus.

Statistical Analysis {#s2e}
--------------------

Continuous variables were analyzed by the Student\'s t test, and the results were expressed as mean ± standard deviation. Dichotomous variables were analyzed by the x2 test. We used Spearman rank correlation to examine the association between SUVmax and protein expression. To explore the association between recurrence-free survival and TIGAR expression, a Kaplan-Meier survival analysis was performed. Two- sided p values of less than 0.05 were considered to be statistically significant. All analyses were performed using SPSS software, version 16.0 (SPSS Inc, Chicago, IL).

Results {#s3}
=======

Clinical and pathological characteristics of patients in relation to SUV~max~ {#s3a}
-----------------------------------------------------------------------------

The clinical and pathological characteristics of the 79 patients with NSCLC in this study are illustrated in [Table 1](#pone-0080576-t001){ref-type="table"}. The patients were aged between 30 and 79 years (mean; 60.85±10.40 years) and included 50 males and 29 females. The mean SUV~max~ was 7.24±4.58, the maximum, minimum and median values were 24.1, 0.7 and 6.6 respectively, and 10 patients had a SUV~max~ \<2.5. Statistical analysis showed that there were no significant differences in SUV~max~ between patients ≥60 years old and patients \<60 years old or between male and females patients.

10.1371/journal.pone.0080576.t001

###### Clinical and pathological characteristics in relation to SUV~max~ in patients with NSCLC.

![](pone.0080576.t001){#pone-0080576-t001-1}

  Characteristic           No. patients     SUVmax     *P*-value
  ----------------------- -------------- ------------ -----------
  Age                                                 
  60 years                      39        6.85±3.81      0.58
  60 years                      40        7.42±4.23   
  Gender                                                 0.37
  Male                          50        7.65±4.27   
  Female                        29        6.54±4.84   
  Tumor size (cm)                                       \<0.01
  ≤3.0                          54        5.62±3.82   
  \>3.0                         25        10.7±4.18   
  Pathology                                             \<0.01
  Squamous                      24        10.60±4.73  
  Adenocarcinoma                55        5.94±4.04   
  Tumor differentiation                                 \<0.01
  Well                          13         4.4±3.1    
  Moderate                      34         7.2±4.2    
  Poor                          32         12.7±4.1   
  Pathological N stage                                  \<0.01
  N0                            55        6.33±4.60   
  N1                            24        9.31±3.89   
  Outcome                                               \<0.01
  Alive                         42        6.13±3.89   
  Dead                          20        9.66±4.15   

SUV~max~  =  maximal standardized uptake value.

However, there were significant differences in SUV~max~ between patients with tumors \>3 cm and those with tumors ≤3 cm in size. In addition, SUV~max~ was statistically different between patients with well, moderate and poorly differentiated tumors; between patients with squamous carcinoma and adenocarcinoma and between patients with pathological stage N0 and N1 tumors (p\<0.01).

Relationship between FDG-PET and immunohistochemical scores of proteins involved in glucose metabolism in tumor cells {#s3b}
---------------------------------------------------------------------------------------------------------------------

We carried out immunohistochemical (IHC) analysis in order to assess the correlation between PET SUV~max~ and the expression of selected proteins associated with glucose metabolism in tumor cells according to their IHC staining scores.

The results are shown in [Figure 1](#pone-0080576-g001){ref-type="fig"} and presented in [Table 2](#pone-0080576-t002){ref-type="table"}. SUV~max~ of FDG showed a negative correlation with TIGAR expression (r = −0.31, p\<0.01). In addition, SUV~max~ was significantly correlated with expression levels of *GLUT1*(r = 0.37, p\<0.01). However, SUV~max~ was weakly correlated with *PKM2* and not correlated with glucose metabolism genes, *LDHA, HK2* or oncogenes, *AKT*.

![Immunohistochemical analysis showed positive staining.\
A: *TIGAR*, B: *GLUT*, C: *HK2*, D: *PKM*, E: *LDHA*, F: *AKT* (magnification, ×400).](pone.0080576.g001){#pone-0080576-g001}

10.1371/journal.pone.0080576.t002

###### Pearson correlation coefficients and p-value between the immunohistochemistry (IHC) staining scores for genes expression associated with glucose metabolism in tumors with SUV~max~.

![](pone.0080576.t002){#pone-0080576-t002-2}

  Factor                        SUVmax  
  --------------------- ------ -------- --------
  *TIGAR* expression     0.31            \<0.01
  *GLUT-1* expression    0.37            \<0.01
  *HK-2* expression      0.08             0.45
  *PKM-2* expression     0.21             0.06
  *LDHA* expression      0.09             0.39
  *AKT* expression       0.04             0.71

There was a significant difference in SUV~max~ between patients with positive and negative expression of *TIGAR* (*P*\<0.01). The mean value of SUV~max~ was 8.29±3.64 in the TIGAR negative cases and 6.31±3.14 in the TIGAR positive cases. Similarly, SUV~max~ was significantly different between patients with positive and negative expression of *GLUT1* (*P*\<0.01). The mean value of SUV~max~ was 6.09±3.60 in the *GLUT1* negative cases and 8.83±5.33 in the *GLUT1* positive cases ([Table 3](#pone-0080576-t003){ref-type="table"}).

10.1371/journal.pone.0080576.t003

###### Correlation between TIGAR or GULT-1 expression and SUV~max~.

![](pone.0080576.t003){#pone-0080576-t003-3}

  Factor                 No. patients    SUVmax     *P*-value
  --------------------- -------------- ----------- -----------
  *TIGAR* expression                                 \<0.01
  Negative                    37        8.29±3.64  
  Positive                    42        6.31±5.14  
  *GLUT-1* expression                                \<0.01
  Negative                    46        6.09±3.60  
  Positive                    33        8.83±5.33  

We further analyzed the impacts of the different expression level of *TIGAR* and *GLUT1* on glucose uptake ([Table 4](#pone-0080576-t004){ref-type="table"}). The maximum SUV~max~ (mean, 10.20±3.40) was observed in patients with negative expression of *TIGAR* and positive expression on *GLUT1*. Conversely, the minimum SUV~max~ (mean, 5.47±3.89) was observed in patients with positive expression of *TIGAR* and negative expression of *GLUT1*.

10.1371/journal.pone.0080576.t004

###### Correlation between expression of *TIGAR* and *GLUT-1* with SUV~max~, based on immunohistochemical (IHC) score.
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                       *TIGAR* (IHC score)  
  -------- ---------- --------------------- -----------
            Negative        6.82±3.17        5.47±3.89
  GLUT-1       46              21               25
            Positive       10.20±3.40        7.54±6.51
               33              16               17

Relationship between TIGAR expression and the biological characteristics and staging grade of NSCLC tumors {#s3c}
----------------------------------------------------------------------------------------------------------

Although *TIGAR* is closely linked to glucose uptake in tumor tissues, there have been few reports on its relationship with the biological characteristics of tumor tissues. Therefore we analyzed *TIGAR* expression levels in tissue samples from 79 patients with NSCLC in relation to age, gender, tumor size, histological type, histological degree and tumor staging. The results are presented in [Table 5](#pone-0080576-t005){ref-type="table"}. These showed that the difference between *TIGAR* expression in respect of patient gender or age (\<60 or ≥60 years) was not significant. Conversely, the difference was significant between *TIGAR* expression in patients with respect to tumor size (≤3 or \>3 cm), histological type (squamous or adenocarcinoma), differentiation degree (well or poor) and staging (N0 or N1).

10.1371/journal.pone.0080576.t005

###### The relationship between *TIGAR* expression and tumor characteristics, based on immunohistochemical (IHC) score.
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                           TIGAR (IHC score)       
  ----------------------- ------------------- ---- --------
  Age                                                0.22
  \<60 years                      21           18  
  ≥60 years                       16           24  
  Gender                                             0.09
  Male                            27           23  
  Female                          10           19  
  Tumor size (cm)                                    0.01
  ≤3                              20           34  
  \>3                             17           8   
  Pathology                                         \<0.01
  Squamous                        18           7   
  Adenocarcinoma                  19           35  
  Tumor differentiation                             \<0.01
  poor                            21           11  
  well                            16           31  
  Pathological N stage                              \<0.01
  N0                              19           36  
  N1                              18           6   

The relationship between TIGAR expression with survival and prognosis of patients with NSCLC {#s3d}
--------------------------------------------------------------------------------------------

In order to assess the impact of *TIGAR* expression on patients\' survival, we plotted Kaplan-Meier survival curves for patients with positive expression and negative expression of *TIGAR* ([Figure 2](#pone-0080576-g002){ref-type="fig"}). The results showed that the survival time of patients whose *TIGAR* was negatively expressed was significantly shorter than for those whose *TIGAR* was positively expressed (*P* = 0.023 according to the log-rank test).

![Kaplan-Meier recurrence-free survival curve according to *TIGAR* expression in patients with NSCLC.\
The survival time of patients with negative expression of *TIGAR* is significantly shorter than those with positive expression of *TIGAR*.](pone.0080576.g002){#pone-0080576-g002}

Discussion {#s4}
==========

Lung cancer has the highest incidence rate of human malignancies and is the leading cause of cancer mortality worldwide. Patients with NSCLC account for 80 to 85% of all patients with lung cancer; therefore, early diagnosis and targeted treatments are critical to improving survival rates of lung cancer patients [@pone.0080576-Watanabe1]. In this respect, FDG-PET molecular imaging techniques have provided major advances in clinical diagnosis of lung cancer. In accordance with previous reports, our study showed that SUV~max~ was closely correlated with tumor size, differentiation degree and pathological type in NSCLC patients. In addition, patients with higher SUV~max~ had an increased probability of lymph node metastasis and a worse prognosis. High SUV~max~ is correlated with an increase in glucose metabolism and the Warburg effect in tumor cells. It is generally acknowledged that the Warburg effect is associated with abnormal expression of glucose metabolism enzymes (*GLUT1, HK2,PKM2, LDHA*), oncogenes (*Ras, MET*), signal transduction kinases (*AMP, AKT*) and mitochondrial proteins (IDH3, COX2), as well as a hypoxic microenvironment in which the expression level of hypoxia-inducible factor 1 (HIF-1) increases [@pone.0080576-Bensinger1]--[@pone.0080576-Herling1]. However, the mechanisms underlying the Warburg effect are not yet fully understood.

In our present study, the expression levels of seven metabolic enzymes associated with glucose metabolism in tumor cells were compared with SUV~max~ in 79 patients with NSCLC. Our results showed that SUV~max~ of FDG uptake was significantly correlated with expression levels of *GLUT1* and *TIGAR*, weakly correlated with *PKM2* and not correlated with glucose metabolism genes, *LDHA, HK2* or oncogenes, *AKT*.

Previous reports have suggested that *GLUT1* has an important role in ^18^F-FDG uptake in patients with lung cancer, soft tissue sarcoma and pancreatic cancer [@pone.0080576-Maiko1], [@pone.0080576-Nguyen1], [@pone.0080576-Tateishi1]. Conversely, Tohma et al. reported low correlation between ^18^F-FDG uptake and *GLUT1* expression in esophageal cancer [@pone.0080576-Tohma1]. Our data demonstrated that *GLUT1* expression was significantly associated with high SUV~max~, supporting earlier reports that *GLUT1* expression contributes to ^18^F-FDG uptake in NSCLC patients.

Notably, this study has provided the first evidence of a correlation between *TIGAR* expression and SUV~max~ on FDG-PET in patients with NSCLC. Our data showed that *TIGAR* expression is negatively correlated with tumor SUV~max~. Furthermore, SUV~max~ was highest in patients who had positive expression of *GLUT1* with negative expression of *TIGAR*. This further demonstrated that *TIGAR* involved in glycolysis in lung cancer and *TIGAR* inhibition could remove the negative regulation of glucose metabolism, thereby increasing glycolysis in tumor cells.

Many experiments that have been performed at the cellular level have confirmed that *TIGAR* can inhibit glycolysis. This is consistent with our clinical observations. It is generally considered that the glycolysis mechanism induced by *TIGAR* bears close similarity to that of the bisphosphatase (FBPase) domain of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2/FBPase-2), in that *TIGAR* expression leads to a reduction in fructose-2, 6-bisphosphate (Fru-2, 6-BP) levels, thereby suppressing glycolytic flux and tumor growth. Fru-2, 6-BP is a potent allosteric regulator of PFK1, an early enzyme in the glycolytic pathway. Furthermore, the decrease in Fru-2, 6-BP levels may lead to decreased GK (the hepatic isoform of hexokinase) and increased G6Pase levels [@pone.0080576-Wu1], providing an additional means by which *TIGAR* can negatively regulate glycolysis.

Activation of glycolysis is not only beneficial to tumor metabolism for energy production and proliferation, but can also activate multiple transcription factors associated with oncogenes and tumor development, such as sterol regulatory element binding protein (SREBP) which is involved in fatty acid synthesis [@pone.0080576-Zhao1]. Therefore, these glycolytic genes have also been the focus of studies on tumor development. It is increasingly apparent that *TIGAR* may play other significant roles in controlling processes involved in human malignancies; however, the mechanisms remain to be fully understood. It has been suggested that *TIGAR* inhibits tumor growth by acting in a similar manner to the tumor suppressor *P53*. López-Guerra et al. found that high expression of *TIGAR* was positively correlated with chronic lymphocytic leukemia (CLL) sensitivity to Fludarabine, which can induce apoptosis [@pone.0080576-LpezGuerra1]. Madan et al. showed that *TIGAR* could stabilize the retinoblastoma protein and E2F transcription factor 1 (Rb-E2F1) complex leading to cell cycle arrest and inhibition of tumor growth [@pone.0080576-Madan1]. Similarly, Hesegawa found that high expression of *TIGAR* promoted cell cycle arrest and cellular senescence, whereas a *TIGAR* knockout acted to reduce apoptosis [@pone.0080576-Hasegawa1]. However, a conflicting mechanism proposed by Bensaad et al. suggested that *TIGAR* inhibited glycolysis at the cellular level while activating the PPP, which inhibited ROS production and tumor cell apoptosis and autophagy; thereby promoting tumor growth in U2OS and RKO cell lines [@pone.0080576-Bensaad1].

The majority of studies on *TIGAR* have been performed at the cellular level with only a few reports on clinical studies. Therefore, we conducted this study to compare *TIGAR* expression with the clinical characteristics of tumors, and its relationship to prognosis and survival in patients with NSCLC. We demonstrated that *TIGAR* expression was significantly higher in lung adenocarcinoma tissue than in squamous carcinoma (*P*\<0.01), which is consistent with observations of lower SUV in lung adenocarcinoma. We found that well-differentiated NSCLC had higher expression levels of *TIGAR* compared to poorly differentiated NSCLC, indicating increased malignancy. In addition, we showed that patients with negative expression of *TIGAR* were more likely to develop lymph node metastasis than those with positive expression of *TIGAR*. These indicated that *TIGAR* expression was closely correlated with prognosis. Survival curve analysis showed that the survival rate declined significantly in NSCLC patients who had low levels of *TIGAR* expression (*P = *0.023) compared those with high levels. These findings, based on clinical studies of NSCLC tissues, suggest that quantification of TIGAR protein levels may help predict prognosis of patients with NSCLC and cancer treatment targeting TIGAR might become feasible in the future. We have proposed to conduct a trial of a *TIGAR* activator for the treatment of lung cancer in PET-positive mice with the aim of developing potential gene targeted therapies for lung cancer.

In conclusion, the expression of *GLUT1* and *TIGAR* was correlated to SUVmax in NSCLC. This is the first report that describes a significant correlation between the expression of *TIGAR* and SUV~max~, and showed that low expression of *TIGAR* in primary NSCLC tumors was strongly correlated with a worse clinical outcome. These findings indicate that TIGAR may help predict prognosis of cancer patients and facilitate selection of patients for targeted therapies involving *TIGAR* in NSCLC. Further studies are required to identify lung cancer patients who are suitable for *TIGAR*-targeted therapy based on pre-evaluation of FDG uptake.
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